Quantum-Si (QSI) Stock News, Mar-Jun 2025

Quantum-Si (Nasdaq: QSI) announces its participation in a GenomeWeb webinar titled 'From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics' scheduled for June 20, 2025. The one-hour virtual event will feature expert speakers from Quantum-Si, DNAnexus, Olink (Thermo Fisher Scientific), and Northwestern University's Proteomics Center of Excellence. The webinar will focus on crucial strategies for improving proteomics data management, including data accessibility, integration, and standardization across platforms. Key topics include metadata annotation best practices, cross-study dataset normalization, and participation in global standardization initiatives. The event aims to provide valuable insights for researchers, data scientists, and bioinformaticians in the proteomics field.

Quantum-Si (Nasdaq: QSI) announces that Liberate Bio's Director of Platform, Melissa Deck, will present at the Festival of Genomics & Biodata Boston on June 24, 2025. The presentation titled 'Precision Proteomics: Advancing Drug Development with Next-Gen Protein Sequencing' will showcase how QSI's Platinum Pro instrument is being used for protein analysis through single-molecule detection. The talk will highlight protein barcoding applications for nucleic acid-LNP therapeutic development, including single-molecule protein sequencing on a benchtop platform, proteomics and genomics integration, and multiplexed protein screening. Deck brings extensive experience in CRISPR/Cas9 editing, gene therapy, and LNP screening from her leadership roles in biotech and pharma.

Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein analysis, has granted 45,529 restricted stock units (RSUs) to new employees as inducement awards. The grants were made under the company's 2023 Inducement Equity Incentive Plan and approved by the Compensation Committee of QSI's Board of Directors. The RSUs will vest 25% on June 20, 2026, with the remaining amount vesting in 12 equal quarterly installments thereafter, contingent on continued employment. These equity awards were granted as material inducement for new hires joining Quantum-Si, in compliance with Nasdaq Listing Rule 5635(c)(4).

Quantum-Si and ESPCI Paris researchers have developed a groundbreaking method for measuring single-molecule binding kinetics at scale using QSI's Platinum Next-Gen Protein Sequencing instrument. The technique combines protein barcode sequencing with real-time single-molecule interaction data, enabling parallel analysis of protein variants without genotype-phenotype coupling. The method was validated across 20 nanobody variants showing strong correlation with SPR, demonstrating a 1,000-fold range in affinity. The platform allows for high-throughput measurement of tens of thousands of single molecules per run and has potential to scale to over 1,000-member barcode sets. This innovation makes single-molecule analysis more accessible and practical for applications in drug discovery, protein engineering, and disease biology research.

Quantum-Si (Nasdaq: QSI) reported its Q1 2025 financial results, highlighting revenue of $842,000, an 84% increase from Q1 2024. The company successfully launched and delivered its first Platinum® Pro units and expanded its international channel network to 23 partners. Key developments include the on-track progress of Proteus™ Platform, v4 Sequencing Kit (expected Q3 2025), and a new v3 Library Preparation Kit (expected end of 2025). Financial metrics show a gross profit of $486,000 with 58% margin, and operating expenses of $25.6M. The company reported a net loss of $19.2M. Following a $50M registered direct offering in January 2025, QSI holds $232.6M in cash and investments, providing runway into second half of 2027. The company noted challenges in the U.S. market due to NIH funding and tariff uncertainty but remains optimistic about opportunities in pharma, biotech, and international markets.

Quantum-Si (NASDAQ: QSI) has announced the granting of 16,555 restricted stock units (RSUs) to new employees as part of its 2023 Inducement Equity Incentive Plan. The RSUs were granted as inducement awards under Nasdaq Listing Rule 5635(c)(4), specifically designed for new hires who were not previously employed by the company. The vesting schedule includes 25% vesting on June 20, 2026, followed by the remaining amount vesting in 12 equal quarterly installments. The grants are contingent upon continued employment with Quantum-Si through the vesting dates.

Quantum-Si (Nasdaq: QSI) announces an upcoming Nature webinar featuring Dr. Gloria Sheynkman from the University of Virginia on May 15, 2025. The presentation, titled "Precision Proteomics: Next-Gen Protein Sequencing for Proteoform Detection and Characterization," will showcase research utilizing QSI's Platinum® Next-Gen Protein Sequencing™ (NGPS™) platform.

Dr. Sheynkman will present findings from her team's study on tropomyosin proteoforms, demonstrating the platform's capability to detect protein variations at the single-molecule level. The webinar, scheduled for 8:00 a.m. PDT / 11:00 a.m. EDT, highlights QSI's innovative technology that enables single-amino acid resolution and high-specificity detection of endogenous proteins.

Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 15, 2025. The company will host a conference call and webcast at 4:30 PM ET on the same day, featuring President and CEO Jeff Hawkins and CFO Jeff Keyes, who will discuss the financial performance and provide a business update.

Interested participants can join via live webcast through the Investors section of Quantum-Si's website under Events and Presentations, or register for a personalized dial-in number to join the call. A replay of the webcast will be available after the event.

Quantum-Si (Nasdaq: QSI) has begun shipping its latest benchtop protein sequencer, Platinum® Pro, designed to make Next-Gen Protein Sequencing™ more accessible globally. The new system builds upon the original Platinum model with enhanced features including:

• An enlarged touchscreen with intuitive user interface
• Flexible local or cloud-based data analysis options
• Pro Mode for custom application development through a Technology Access Program

The system offers single-molecule precision protein analysis through an integrated workflow and is now available in over 30 countries through direct and channel partner networks. According to CEO Jeff Hawkins, Platinum Pro aims to advance proteomics research and enable new biomarker discoveries.